Download PDF
Pharmacopsychiatry 2006; 39(5): 194-199
DOI: 10.1055/s-2006-948331
Letter

© Georg Thieme Verlag KG Stuttgart · New York

Unrecognised Long-Lasting Tramadol-Induced Delirium in Two Elderly Patients

A Case ReportG. Künig 1 , 2 , S. Dätwyler 2 , A. Eschen 2 , U. Schreiter Gasser 2
  • 1Department of Psychiatry, University of Zurich, Division of Psychogeriatric Medicine, Lenggstrasse 31, Postfach 1931, 8029 Zurich, Switzerland
  • 2Department of Psychiatry, University of Zurich, Division of Gerontopsychiatry, Gerontopsychiatrisches Zentrum Hegibach, Minervastrasse 145, Postfach 1682, 8032 Zurich, Switzerland
Further Information

Publication History

Received 14.11.2005 Revised 20.4.2006

Accepted 6.6.2006

Publication Date:
30 August 2006 (online)

Also available at
    Permissions and Reprints

We present the cases of two elderly patients with intermittent long-term tramadol intake against chronic back pain. Over a period of more than two years they experienced fluctuating confusional states and cognitive deficits, reversible only after discontinuation of tramadol. According to the DSM IV-criteria, an unrecognised recurrent tramadol-induced delirium can be diagnosed in both cases. Although tramadol may represent a well established safe therapy for chronic non-malignant pain in the elderly, these cases demonstrate that it should be applied with caution even in healthy subjects.

References

  • 1 Bailer U, Fischer P, Kufferle B, Stastny J, Kasper S. Occurrence of mirtazapine-induced delirium in organic brain disorder.  Int Clin Psychopharmacol. 2000;  15 239-243
    CrossrefPubMedGoogle Scholar
  • 2 Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients.  J Am Geriatr Soc. 1998;  46 620-625
    PubMedGoogle Scholar
  • 3 Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel RR, Schmidt LG. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.  Pharmacopsychiatry. 2004;  37 ((Suppl 1)) 39-45
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Devulder J, De Laat M, Dumoulin K, Renson A, Rolly G. Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.  Acta Clin Belg. 1996;  51 184-186
    PubMedGoogle Scholar
  • 5 Elie M, Cole MG, Primeau FJ, Bellavance F. Delirium risk factors in elderly hospitalized patients.  J Gen Intern Med. 1998;  13 204-212
    CrossrefPubMedGoogle Scholar
  • 6 Ersek M, Cherrier MM, Overman SS, Irving GA. The cognitive effects of opioids.  Pain Manag Nurs. 2004;  5 75-93
    CrossrefPubMedGoogle Scholar
  • 7 Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.  Arch Intern Med. 2003;  163 2716-2724
    CrossrefPubMedGoogle Scholar
  • 8 Grond S, Sablotzki A. Clinical pharmacology of tramadol.  Clin Pharmacokinet. 2004;  43 879-923
    CrossrefPubMedGoogle Scholar
  • 9 Houlihan DJ. Serotonin syndrome resulting from co-administration of tramadol, venlafaxine, and mirtazapine.  Ann Pharmacother. 2004;  38 411-413
    CrossrefPubMedGoogle Scholar
  • 10 Ishikawa E, Yanaka K, Sugimoto K, Ayuzawa S, Nose T. Reversible dementia in patients with chronic subdural hematomas.  J Neurosurg. 2002;  96 680-683
    PubMedGoogle Scholar
  • 11 Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. The impact of different diagnostic criteria on prevalence rates for delirium.  Dement Geriatr Cogn Disord. 2003;  16 156-162
    CrossrefPubMedGoogle Scholar
  • 12 Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. Delirium among patients with and without dementia: does the diagnosis according to the DSM-IV differ from the previous classifications?.  Int J Geriatr Psychiatry. 2004;  19 271-277
    CrossrefPubMedGoogle Scholar
  • 13 Lee KU, Won WY, Lee HK, Kweon YS, Lee CT, Pae CU, Bahk WM. Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study.  Int Clin Psychopharmacol. 2005;  20 311-314
    CrossrefPubMedGoogle Scholar
  • 14 Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili J, Scheltens P, Vellas B, Touchon J. Mild Cognitive Impairment in medical practice: critical review of the concept and new diagnostic procedure. Report of the MCI working group of the European Consortium on Alzheimer's disease (EADC).  J Neurol Neurosurg Psychiatry. 2006;  , March 20 [Epub ahead of print]
    PubMedGoogle Scholar
  • 15 Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6.  Clin Pharmacol Ther. 1996;  60 636-644
    CrossrefPubMedGoogle Scholar
  • 16 Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain.  Drug Saf. 1996;  15 8-29
    PubMedGoogle Scholar
  • 17 Soyka M, Backmund M, Hasemann S. Tramadol use and dependence in chronic noncancer pain patients.  Pharmacopsychiatry. 2004;  37 191-192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Spiller HA, Gorman SE, Villalobos D, Benson BE, Ruskosky DR, Stancavage MM, Anderson DL. Prospective multicenter evaluation of tramadol exposure.  J Toxicol Clin Toxicol. 1997;  35 361-364
    PubMedGoogle Scholar
  • 19 Weber JB, Coverdale JH, Kunik ME. Delirium: current trends in prevention and treatment.  Intern Med J. 2004;  34 115-121
    CrossrefPubMedGoogle Scholar

Correspondence

Gabriella Künig

Department of Psychiatry·University of Zurich·Division of Psychogeriatric Medicine

Lenggstrasse 31·Postfach 1931·8029 Zürich·Switzerland

Phone: +41/44/384 27 82

Fax: +41/44/384 26 87

Email: gabriella.kuenig@puk.zh.ch

      >